Weitai at 15: Five Key Decisions from a Small OEM Shop to an Integrated Cosmetics-Medical Device Manufacturing Center

<h1>Weitai at 15: Five Key Decisions That Took Us from a Small OEM Shop to an Integrated Cosmetics-Medical Device Manufacturing Center</h1> <p>In 2001, our founder started out in the cosmetics industry. Back then there was no factory and no certifications, just a strong interest in functional skincare and medical devices, and a willingness to learn the trade the slow way.</p> <p>By 2026, Weitai Group had grown into an integrated cosmetics-medical device manufacturing group with <strong>four production bases, 100+ Class II medical device registrations, 26 invention patents, and 30+ international patents</strong>, serving more than <strong>1,000 brand clients</strong>. The four bases cover over <strong>150,000 square meters</strong>, with a daily output of 6 million units and 1 million pairs of lyophilized powder per day.</p> <p>From a "small OEM shop" to an "integrated cosmetics-medical device manufacturing center," the pitfalls and choices along the way far exceeded what outsiders see. In this article, we break down <strong>five key decisions</strong>, not as success stories, but for the industry logic and hands-on lessons behind each one.</p> <h2>Key Decision 1: 2012, Launching an Own Brand from Pure OEM — the Birth of "Shiwei Landai"</h2> <p>The biggest problem with early contract manufacturing was that <strong>pricing power was never in our own hands</strong>. Brands pushed prices down, payment terms stretched, and demand fluctuated, so OEM margins kept thinning.</p> <p>In 2012, Weitai did something uncommon in the industry at the time: <strong>partnering with Baiyunshan Bitabi Biopharmaceutical of Guangzhou Pharmaceutical Holdings to found the "Shiwei Landai" brand</strong>, formally entering the own-brand arena from pure OEM.</p> <p><strong>Why launch an own brand?</strong></p> <p>The logic was simple: an own brand validates your formulation capability and production system, and shows OEM clients that "what we make ourselves sells well too." That is more convincing than any sales pitch.</p> <p>Shiwei Landai later became one of Weitai Group's core own brands, with its lyophilized powder series surpassing 140,000+ units in cumulative sales. The essence of this decision: <strong>use the own brand to validate OEM capability, and let OEM experience feed back into the own brand</strong>.</p> <p>More brands followed, including <strong>Beifu Yinzi, Yiweilan, Siniman, Meifu, and Duoni</strong>, covering different segments of functional skincare. All seven own brands have complete formulation and filing systems.</p> <h2>Key Decision 2: 2016, Earning Dual EU ISO 22716 and US GMPC Certification — Turning Export Qualifications into an OEM Moat</h2> <p>In 2016, Weitai passed both <strong>EU ISO 22716</strong> and <strong>US GMPC</strong> international certifications. These are the essential qualifications for exporting cosmetics to the European and US markets. Many domestic contract manufacturers hold one or the other; holding both at the same time was rare.</p> <p><strong>Why insist on both?</strong></p> <p>Because client needs were diverging. Some clients exported to the EU, some to the US, and some entered both markets at once. A factory with only one certification meant clients had to split production across two factories, a real cost for brand supply chain management.</p> <p>With both certifications, <strong>one Weitai factory could cover the compliance needs of both the European and American markets</strong>, a tangible convenience for brand clients then expanding into cross-border e-commerce and exports.</p> <p>The effect: after 2016, cross-border e-commerce brands and export-oriented brands began appearing among Weitai's OEM clients, diversifying a client base once concentrated in domestic channels.</p> <h2>Key Decision 3: 2018, Launching Industry-Academia-Research Collaboration</h2> <p>In 2018, Weitai built deep industry-academia-research collaboration starting with <strong>its in-house R&D center</strong>, later extending to Anhui Medical University, Xiangya Hospital of Central South University, and Southern Medical University.</p> <p><strong>Industry-academia-research is not about hanging up a plaque; it is about solving real technical problems.</strong></p> <p>Two concrete cases:</p> <p><strong>Case 1: 121C high-temperature collagen technology.</strong> The Anhui Medical University team helped Weitai solve the technical challenge of keeping recombinant collagen active through 121C sterilization for 40 minutes. This solved the industry pain point of collagen thermal stability and earned an invention patent. Simply put: ordinary collagen is destroyed by high-temperature sterilization, while Weitai's collagen survives 121C sterilization, safeguarding both shelf life and safety.</p> <p><strong>Case 2: the core lyophilized powder series.</strong> The lyophilized powder series has surpassed 140,000+ units in cumulative sales. The partner university, a national "Project 211" institution, provided academic endorsement for Weitai's freeze-drying technology.</p> <p>The essence of industry-academia-research: <strong>converting laboratory results into a factory's mass-production capability</strong>. Not data in papers, but process parameters on the production line.</p> <h2>Key Decision 4: 2021, Founding Hunan Weitai Biopharmaceutical — from Cosmetics-Only to Dual Cosmetics and Medical Device Tracks</h2> <p>In 2021, Hunan Weitai Biopharmaceutical Co., Ltd. was founded in Ningxiang, Changsha, focusing on the R&D and manufacturing of <strong>Class II/III medical devices</strong>.</p> <p><strong>Why medical devices?</strong></p> <p>Because cosmetics and medical devices face entirely different market demands:</p> <p>Cosmetics serve daily skincare, beauty salons, and e-commerce brands. Demand is high, but homogeneous competition is severe, and brands need <strong>differentiated formulations and fast delivery</strong>.</p> <p>Medical devices serve hospitals, pharmacies, and post-procedure repair after medical aesthetics. Barriers are high (registrations required), but client stickiness and repurchase rates are stronger and margins are better. Brands need <strong>registrations, clinical data, and compliance assurance</strong>.</p> <p>Weitai's layout: <strong>Guangzhou/Foshan for cosmetics, Hunan for medical devices</strong>, two tracks in parallel. Hunan Yian Biotechnology holds 100+ Class II medical device registrations across five categories: medical dressings, hemostatic materials, dental materials, gynecological dressings, and radiation protection.</p> <p>The strategic significance: <strong>brands can complete the full development of both cosmetics and medical device products within one Weitai factory</strong>, without engaging two separate contract manufacturers. That is the core competitiveness of "cosmetics-medical device integration."</p> <h2>Key Decision 5: 2023-2026, Four Bases Completed, National High-tech Recognition, and International Standards Participation</h2> <p>By 2023, both Guangdong Weitai Biotechnology and Hunan Weitai Biotechnology had been recognized as <strong>National High-tech Enterprises</strong>. In 2025, Weitai appeared at the 66th Guangzhou International Beauty Expo showcasing integrated cosmetics-medical device solutions.</p> <p>In 2026, <strong>two international standards for recombinant collagen involving Weitai were approved for project initiation</strong>, a shift from industry participant to rule maker.</p> <p>The four bases have clear divisions:</p> <p><strong>Guangzhou Baiyun base</strong> (Guangdong Weitai Biotechnology): cosmetics OEM/ODM/OBM contract manufacturing, daily capacity of 1 million pairs of lyophilized powder and 1 million sheet masks.</p> <p><strong>Foshan Nanhai base</strong> (Guangdong Weitai Biotechnology Foshan plant): cosmetics manufacturing, dual-certified ISO 22716 + GMPC.</p> <p><strong>Zhaoqing base</strong> (Guangdong Jinan Gene Bioengineering): industrialization of bioactive materials, large-scale recombinant collagen production.</p> <p><strong>Hunan Ningxiang base</strong> (Hunan Weitai Biopharmaceutical + Hunan Yian Biotechnology): core medical device production base, daily capacity of 1 million pairs of lyophilized powder, 100+ Class II registrations.</p> <p>Total site area exceeds 150,000 square meters, with 65 automated production lines, a library of 10,000+ mature formulations, and 1,000+ brand clients served.</p> <h2>Fifteen Years On: The Survival Logic of Contract Manufacturing</h2> <p>Looking back on these 15 years, every Weitai decision revolved around one core logic: <strong>a contract manufacturer cannot remain just an "executor"; it must become a "solution provider."</strong></p> <p>When brands look for a contract manufacturer, what they truly need is not "help me produce," but: <strong>formulation R&D capability, registration and filing support, capacity assurance, compliance endorsement, and supply chain integration</strong>. Weitai delivers all of these.</p> <p>100+ Class II registrations is not a numbers game; each certificate corresponds to a real product, a real registration process, and real compliance verification. 26 invention patents are not wall decorations; they are outcomes of solving concrete technical problems. 1,000+ brand clients is not a marketing line; it is the trust built over 15 years of OEM experience.</p> <p>If you are looking for a partner that can do both cosmetics and medical devices, with both formulation R&D capability and registration experience, Weitai Group may be the partner you need.</p> <p><strong>Contact Weitai Group</strong>: 15367392630 (WeChat available), website <a href="https://weitaigd.com">weitaigd.com</a></p>